The experimental drug fenebrutinib worked better than Aubagio, an approved therapy, for reducing relapse rates in MS, new ...

Columnist Desiree Lama is reconnecting with her love of plants and being outside after starting an outdoor garden at her new ...

Medicaid coverage of highly effective disease-modifying therapies for MS varies widely across the U.S., with no coverage in ...

Mapi Pharma’s GA Depot was associated with stable disability scores over time in people with both RMS and PPMS, data show.

A new method replicated the findings of a previous clinical trial of Tecfidera in people with relapsing-remitting MS, a study ...

Real-world use of an MS blood test shows how it helps monitor disease activity and guide treatment decisions in U.S. patients ...

Guest columnist Lindsay Kelly says that receiving her husband Rhead's MS diagnosis gave her a helpful framework for ...

Long-term treatment with Ocrevus preserved hand and walking function for people with early active relapsing-remitting MS, a ...

Briumvi’s Phase 3 trial of an at-home injection has completed enrollment, testing an under-the-skin version against IV ...

Bionxt has completed manufacturing of a batch of BNT23001, its under-the-tongue formulation of cladribine, for use in MS ...

A new analysis suggests having diabetes may significantly increase a person's risk of MS, though no evidence was found a ...

The decision to get an MS-accessible minivan didn't come easy, says columnist Ben Hofmeister, but it has proved to be the right one.